AAAMS

DECEMBER 16, 2024

The world of aesthetic medicine is evolving rapidly, with non-surgical cosmetic procedures leading the way in popularity. Patients today seek treatments that offer impressive results with minimal downtime, making these procedures a must-know for practitioners aiming to stay ahead of the curve. If you’re looking to enhance your skills and meet growing patient demands, mastering these top non-surgical techniques is essential.

Chemical Peels 52

Chemical Peels Microneedling Social Media Surgery 52

Enlightened Beauty

DECEMBER 16, 2024

Hey beautiful! Ready to supercharge your acne treatment journey and attain the healthy skin you deserve? Let's talk about the magic of facial add-ons they're like your skin's secret power-ups, and honey, they're about to become your new best friend! Managing acne isn't just about tackling breakouts (though we'll definitely handle those!). It's more like creating a sacred ritual that nurtures your skin's health from the inside out, bringing it back into perfect harmony.

Facials 52

Facials Chemical Peels Scarring Microneedling 52

Dermatology Times

DECEMBER 16, 2024

Michael Lewitt, MD, FAAD, highlighted the importance of personalized care, the decision-making process in psoriasis treatment, and the role ofpatient education.

Treatments 60

Treatments Education 60

Salon Today

DECEMBER 16, 2024

45

45

US Dermatologt Partners

DECEMBER 16, 2024

As women enter menopause, they experience a variety of skin changes. Hormonal shifts, especially the drop in estrogen, lead to issues such as skin dryness, wrinkles, sagging, uneven tone, age spots, hair thinning, and even acne. While these changes are normal, many women want to maintain healthy, youthful-looking skin as they age. According to Dr. Alexandra Theriault of U.S.

Skincare 36

Skincare Chemical Peels Rosacea Microneedling 36

Dermatology Times

DECEMBER 16, 2024

The supplemental New Drug Application is supported by positive results from the INTEGUMENT-PED and INTEGUMENT-OLE trials.

Dermatitis 41

Dermatitis 41

Dermatology Times

DECEMBER 16, 2024

The approval is based on positive data stemming from the ADORING clinical trial program.

Dermatitis 41

Dermatitis Clinic 41

Salon Today

DECEMBER 16, 2024

Management 40

Management 40

Dermatology Times

DECEMBER 16, 2024

A panelist discusses how selecting the optimal laser device requires careful consideration of wavelength, pulse duration, and spot size to effectively target specific skin concerns while minimizing potential adverse effects.

36

36

The Dermatology Digest

DECEMBER 16, 2024

Arcutis Biotherapeutics, Inc. has submitted of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for roflumilast) cream 0.05% (Zoryve) for mild to moderate AD in children aged 2 to 5. When choosing a therapy for very young children living with AD, healthcare providers and caregivers have to account for unique considerations for pediatric patients, including sensitive skin, and select a medication that is appropriate for long-term use by a child with a chro

Safety 36

Safety Sensitive Skin Dermatitis Dermatology 36

Dermatology Times

DECEMBER 16, 2024

Increased awareness for prurigo nodularis may help to usher in a new era of timelier and more targeted treatment.

Treatments 36

Treatments 36

Spa Industry Association

DECEMBER 16, 2024

Spa treatments are, by nature, hands on, so consent isnt perhaps something that youd think of as it seems implied. However, theres far more to it than many people realize. Informed consent is an essential aspect of ethical practice in the spa industry and it forms the backbone of legal compliance in spa operations. Want to ensure you always protect your spas practice and clients?

Ethics 52

Ethics Legal Treatments Medical 52

Dermatology Times

DECEMBER 16, 2024

Topical treatments with plant extracts improved skin hydration and elasticity while reducing melanin and erythema.

Extractions 36

Extractions Hydration Treatments 36

The Dermatology Digest

DECEMBER 16, 2024

Patient enrollment is open for a confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL). HyBryte is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by safe, visible light approximately 24 hours later.

Hospital 36

Hospital Clinic Therapy Dermatology 36

Dermatology Times

DECEMBER 16, 2024

Nemolizumab is intended for use in combination with topical corticosteroids and/or calcineurin inhibitors in this indication.

Dermatitis 36

Dermatitis 36

Dermatology Times

DECEMBER 16, 2024

Join Dermatology Times quarterly editor in chief Aaron Farberg, MD, as he highlights significant advancements in gene expression profile testing for cutaneous melanoma.

Dermatology 36

Dermatology 36

Dermatology Times

DECEMBER 16, 2024

Panelists discuss how the Effisayil 2 trial included diverse patient demographics across different spesolimab dose groups, with baseline characteristics such as age, disease severity, and history of GPP flares influencing the treatment outcomes and safety data.

Safety 36

Safety Treatments 36

Dermatology Times

DECEMBER 16, 2024

Panelists discuss how factors such as tumor size, location, patient age, and overall health guide the decision between surgical excision and nonsurgical treatments such as topical therapies or radiation for managing basal cell carcinoma (BCC) effectively.

Therapy 36

Therapy Management Treatments 36

Dermatology Times

DECEMBER 16, 2024

Panelists discuss how the efficacy data from the Effisayil 2 trial demonstrate that spesolimab significantly delayed the time to first GPP flare and reduced flare severity, highlighting its potential as an effective treatment for preventing life-threatening flares in GPP patients.

Treatments 36

Treatments 36

Dermatology Times

DECEMBER 16, 2024

Melodie Young, MSN, A/GNP-C, discusses how to effectively communicate with patients about managing itch in prurigo nodularis, offering practical tips such as setting realistic expectations, emphasizing the importance of consistent skin care routines, and exploring both pharmacologic and non-pharmacologic strategies to alleviate discomfort.

Management 36

Management 36

Dermatology Times

DECEMBER 16, 2024

Melodie Young, MSN, A/GNP-C, discusses how clinical and practical considerations, such as disease severity, patient preferences, and comorbidities, should guide the selection of treatment for prurigo nodularis, and emphasizes the importance of educating patients about the role of systemic therapies, addressing their concerns, and improving awareness of available treatment options.

Treatments 36

Treatments Education Therapy Clinic 36

Dermatology Times

DECEMBER 16, 2024

Click here to answer today's poll and read more about practice management around the holiday season.

Management 36

Management 36

Dermatology Times

DECEMBER 16, 2024

Melodie Young, MSN, A/GNP-C, discusses how the FDA-approved systemic treatments for prurigo nodularis, dupilumab and nevolizumabnemolizumab, differ in their mechanisms of actiondupilumab targeting IL-4 and IL-13, and nevolizumabnemolizumab targeting IL-31and highlights their similar efficacy in reducing pruritus and lesion size, while also considering differences in safety profiles and treatment considerations.

Treatments 36

Treatments Safety 36